Symbol classroom

ADC

Chart the move, read why OppHub America is covering it, then watch or talk it through — not a Google Finance clone.

ADC

TradingView chart · search any symbol inside the widget · informational only

Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice

0 watching· join free Discuss in Community Join Community

Learn the move

Use this page as a short classroom: (1) scan the chart for the recent move, (2) read OppHub America Insider / Policy / company notes on ADC, (3) note what to watch next, then (4) add ADC to Watch or take the conversation to Community / Club.

Money angle — Akeso is advancing its pipeline, aiming to address limitations of current treatments. Investors monitoring the oncology space may watch for further clinical data on AK158D1 and other candidates in Akeso's portfolio.

Latest coverage on ADC

Recent OppHub America stories tagged ADC — Insider, Policy, CEO Desk, and market catalysts

ADC Form 4 insiders →ADC policy →CEO Desk →Explore →

PolicySeptember 17, 2026

$ADC

$CDE

Akeso's ADC AK158D1 Gains China Phase I Clearance

Akeso, Inc. (9926.HK) announced its investigational bispecific antibody-drug conjugate AK158D1 targeting EGFR and TROP2 has received Phase I clinical trial clearance from China's NMPA. This marks Akeso's fourth clinical-stage ADC candidate, advancing its immuno-oncology strategy.

oil gasutilitiesclean energy

Akeso is advancing its pipeline, aiming to address limitations of current treatments. Investors monitoring the oncology space may watch for further clinical data on AK158D1 and other candidates in Akeso's portfolio.

Read desk note →Chart $ADC

Same-sector peers

Compare nearby names in the classroom

Trade this symbol

End-of-day delayed data · not investment advice · some links are affiliate / referral